NICE Guidance 217 (April 2022) recommends offering sodium valproate first line to males, females aged 10 years or younger who are unlikely to need treatment until childbearing age and women who are unable to have children.
For women of childbearing age, NG 217 recommends offering lamotrigine or levetiracetam first line.